Clinical Trial Update: A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Multiple Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children With Achondroplasia [Phase 2]

View source ↗

Summary

A Phase 2 dose-escalation trial is evaluating safety, efficacy, and pharmacokinetics of weekly subcutaneous TransCon CNP in children with Achondroplasia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Achondroplasia

Drugs mentioned

• TransCon CNP (C-type natriuretic peptide prodrug)

Snippet

Sponsor: Ascendis Pharma A/S | Conditions: Achondroplasia | Phase 2 | Status: UNKNOWN